Nuno Cerveira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/47172/publications.pdf

Version: 2024-02-01

687363 552781 36 714 13 26 citations h-index g-index papers 36 36 36 1217 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently. Current Treatment Options in Oncology, 2021, 22, 49.	3.0	1
2	Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice. Acta Medica Portuguesa, 2019, 32, 550.	0.4	2
3	Negative MR4·Ochronic myeloid leukaemia and its possible implications for treatmentâ€free remission. British Journal of Haematology, 2019, 186, e181-e184.	2.5	1
4	Evidence-Based Criteria for Tyrosine Kinase Inhibitor Interruption in Pregnancy. Journal of Clinical Oncology, 2019, 37, 89-90.	1.6	3
5	Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. BMC Cancer, 2018, 18, 1245.	2.6	15
6	Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report. BMC Cancer, 2018, 18, 1229.	2.6	11
7	Diagnosis, complications and management of chronic neutrophilic leukaemia: A case report. Oncology Letters, 2015, 9, 2657-2660.	1.8	8
8	POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15). Molecular Cancer, 2013, 12, 5.	19.2	12
9	Novel 5′ Fusion Partners of ETV1 and ETV4 in Prostate Cancer. Neoplasia, 2013, 15, 720-IN6.	5.3	36
10	Assessment of Fusion Gene Status in Sarcomas Using a Custom Made Fusion Gene Microarray. PLoS ONE, 2013, 8, e70649.	2.5	3
11	Genetic and clinical characterization of 45 acute leukemia patients with <i>MLL</i> gene rearrangements from a single institution. Molecular Oncology, 2012, 6, 553-564.	4.6	19
12	Potential Downstream Target Genes of Aberrant ETS Transcription Factors Are Differentially Affected in Ewing's Sarcoma and Prostate Carcinoma. PLoS ONE, 2012, 7, e49819.	2.5	21
13	Genetic and Clinical Characterization of 45 Acute Leukemia Patients with MLL Gene Rearrangements From a Single Institution Blood, 2012, 120, 2477-2477.	1.4	0
14	Prognostic Impact of High Hematogones in Acute Myeloid Leukemia. Blood, 2012, 120, 1435-1435.	1.4	0
15	Acute megakaryoblastic leukemia with a fourâ€way variant translocation originating the <i>RBM15–MKL1</i> fusion gene. Pediatric Blood and Cancer, 2011, 56, 846-849.	1.5	16
16	<i>MLL</i> -SEPTIN gene fusions in hematological malignancies. Biological Chemistry, 2011, 392, 713-724.	2.5	52
17	A novel spliced fusion of MLL with CT45A2in a pediatric biphenotypic acute leukemia. BMC Cancer, 2010, 10, 518.	2.6	9
18	Coexistence of alternative MLL–SEPT9 fusion transcripts in an acute myeloid leukemia with t(11;17)(q23;q25). Cancer Genetics and Cytogenetics, 2010, 197, 60-64.	1.0	13

#	Article	IF	CITATIONS
19	Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. Leukemia Research, 2010, 34, 615-621.	0.8	19
20	Both SEPT2 and MLL are down-regulated in MLL-SEPT2therapy-related myeloid neoplasia. BMC Cancer, 2009, 9, 147.	2.6	11
21	Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin. Familial Cancer, 2009, 8, 203-208.	1.9	11
22	CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Modern Pathology, 2009, 22, 744-752.	5.5	23
23	A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis. Molecular Cancer, 2009, 8, 5.	19.2	25
24	Structural and Expression Changes of Septins in Myeloid Neoplasia. Critical Reviews in Oncogenesis, 2009, 15, 91-115.	0.4	5
25	Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor. Pediatric Blood and Cancer, 2008, 51, 554-557.	1.5	8
26	A novel MLL-SEPT2 fusion variant in therapy-related myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 2008, 185, 62-64.	1.0	4
27	Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. Cancer Genetics and Cytogenetics, 2008, 187, 45-49.	1.0	13
28	Molecular characterization of the MLL-SEPT6 fusion gene in acute myeloid leukemia: identification of novel fusion transcripts and cloning of genomic breakpoint junctions. Haematologica, 2008, 93, 1076-1080.	3.5	17
29	Molecular characterization of a rare MLL–AF4 (MLL–AFF1) fusion rearrangement in infant leukemia. Cancer Genetics and Cytogenetics, 2007, 178, 61-64.	1.0	2
30	Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 379-385.	2.8	17
31	TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN Lesions. Neoplasia, 2006, 8, 826-832.	5.3	225
32	Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. Journal of Molecular Medicine, 2006, 84, 911-918.	3.9	54
33	Multimodal genetic diagnosis of solid variant alveolar rhabdomyosarcoma. Cancer Genetics and Cytogenetics, 2005, 163, 138-143.	1.0	13
34	Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. International Journal of Cancer, 2004, 108, 592-595.	5.1	27
35	Karyotypic divergence and convergence in two synchronous lung metastases of a clear cell sarcoma of tendons and aponeuroses with $t(12;22)(q13;q12)$ and type 1 EWS/ATF1. Cancer Genetics and Cytogenetics, 2003, 145, 121-125.	1.0	5
36	Detection of prognostic significant translocations in childhood acute lymphoblastic leukaemia by one-step multiplex reverse transcription polymerase chain reaction. British Journal of Haematology, 2000, 109, 638-640.	2.5	13

3